Saltar al contenido principal
Elsevier

Machine Learning in Drug Development: Part 1

  • 1 Edición, Volumen 64 - 17 de octubre de 2025
  • Última edición
  • Editores: Joy Feng, Katherine Seley-Radtke
  • Idioma: Inglés

Machine Learning in Drug Development: Part One, Volume 64 in the Annual Reports on Medicinal Chemistry series, highlights new advances in the field. Chapters in this release inc… Leer más

Descripción

Machine Learning in Drug Development: Part One, Volume 64 in the Annual Reports on Medicinal Chemistry series, highlights new advances in the field. Chapters in this release include Artificial Intelligence in Small Molecule and Nucleic Acid Research: A Review, AI-aided Drug Development for Protein Degraders: Design, Lead Identification, and Optimization, AI-aided Drug Development for Protein Degraders: Biology Validation, Disease-association, Drug Repurposing, Transforming Modern Drug Discovery with Machine Learning, Artificial Intelligence in the Development of Antiviral Drugs: Progress and Applications, Artificial Intelligence for Drug Target Identification, and Machine Learning in Proteomic Biomarker Discovery.

Puntos claves

  • Provides the authority and expertise of leading contributors from an international board of authors
  • Presents the latest release in Annual Reports on Medicinal Chemistry series
  • Updated release includes the latest information in the field

De interès para

Ideally suited for chemists engaged in multidisciplinary teams for drug discovery including medicinal chemists and others involved in chemical biology and bio-organic disciplines and computational chemistry

Índice

1. Artificial Intelligence in Small Molecule and Nucleic Acid Research: A Review

2. AI-aided Drug Development for Protein Degraders: Design, Lead Identification, and Optimization

3. AI-aided Drug Development for Protein Degraders: Biology Validation, Disease-association, Drug Repurposing

4. Transforming Modern Drug Discovery with Machine Learning

5. Artificial Intelligence in the Development of Antiviral Drugs: Progress and Applications

6. Artificial Intelligence for Drug Target Identification

7. Machine Learning in Proteomic Biomarker Discovery

Detalles del producto

  • Edición: 1
  • Última edición
  • Volumen: 64
  • Publicado: 17 de octubre de 2025
  • Idioma: Inglés

Sobre los editores

JF

Joy Feng

Joy is an Associate Professor of Pediatrics at Emory University with a 25-year experience in the pharmaceutical industry. She received her B.S. from Peking University School of Pharmaceutical Sciences, her Ph.D. in Medicinal Chemistry from Dr. Raymond Bergeron’s lab at the University of Florida School of Pharmacy, and postdoctoral training in enzymology in Dr. Karen Anderson’s lab at Yale University School of Medicine. Joy’s research focuses on drug mechanisms of action, drug combinations, drug resistance, drug metabolism, off-target effects, and toxicity. Joy contributed to the approval of three marketed drugs: Emtricitabine (FTC) for HIV, Sofosbuvir for HCV, and is one of the inventors of Remdesivir, the first FDA-approved direct antiviral for treating COVID-19, and Obeldesivir (GS-5245), currently in clinical trials for the treatment of RSV infection.

Afiliaciones y experiencia
Associate Professor and Associate Director Division of the Laboratory of Biochemical Pharmacology Department of Pediatrics Emory University School of Medicine Children’s Healthcare of Atlanta Atlanta, USA

KS

Katherine Seley-Radtke

Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as the Program Director for UMBC’s Chemistry-Biology Interface graduate training program funded by NIH since 2007. This program promotes hands on cross disciplinary research for almost 50 PhD students from four departments at UMBC and UMB. She is currently the Immediate Past President and Secretary-Elect for the International Society of Nucleosides, Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy, Molecules – Chemical Biology, and Current Protocols in Chemical Biology.
Afiliaciones y experiencia
Professor of Chemistry and Biochemistry, University of Maryland, Baltimore County, MD, USA

Ver libro en ScienceDirect

Lee Machine Learning in Drug Development: Part 1 en ScienceDirect